Yoshimura Koji, Ohara Hiroki, Ichioka Kentaro, Terada Naoki, Matsui Yoshiyuki, Terai Akito, Arai Yoichi
Department of Urology, Kurashiki Central Hospital, Kurashiki, Okayama, Japan.
Urology. 2003 Apr;61(4):786-90. doi: 10.1016/s0090-4295(02)02444-5.
To examine the frequency of and risk factors for nocturia in patients with symptomatic benign prostatic hyperplasia (BPH), and the degree of improvement of nocturia after treatment for BPH.
A total of 505 consecutively selected, newly diagnosed patients with symptomatic BPH were evaluated in studies examining frequency of and risk factors for nocturia. We analyzed the relationships between nocturia assessed by International Prostate Symptom Score (IPSS) and other parameters, including age, prostate volume, serum prostate-specific antigen level, and uroflow variables. Other studies examining the impact of conservative and invasive treatments on nocturia were also conducted using 165 patients receiving tamsulosin and 138 undergoing transurethral resection of the prostate (TURP).
Overall, 359 of the 505 patients (71.1%) answered that they arose at least twice for urination at night. Patient age, score of urgency, and functional bladder capacity were each significantly associated with nocturia. Tamsulosin therapy and TURP significantly reduced the number of episodes of nocturia in 17.9% and 32.2% of patients, respectively. These rates of improvement were lowest for nocturia among the seven individual symptom scores.
In this study using selected cohorts, the frequency of nocturia in patients with BPH was higher than that in community-based studies. Although we cannot estimate patients' satisfaction by the observed changes in scores, the rates of improvement were lowest for nocturia among the seven symptoms of IPSS after conservative and invasive treatments for BPH.
研究有症状的良性前列腺增生（BPH）患者夜尿症的发生频率及危险因素，以及BPH治疗后夜尿症的改善程度。
在研究夜尿症发生频率及危险因素时，共纳入了505例连续入选的新诊断有症状BPH患者。我们分析了国际前列腺症状评分（IPSS）评估的夜尿症与其他参数之间的关系，这些参数包括年龄、前列腺体积、血清前列腺特异性抗原水平和尿流变量。还对165例接受坦索罗辛治疗的患者和138例接受经尿道前列腺切除术（TURP）的患者进行了其他研究，以探讨保守和侵入性治疗对夜尿症的影响。
总体而言，505例患者中有359例（71.1%）回答他们夜间至少起床排尿两次。患者年龄、尿急评分和功能性膀胱容量均与夜尿症显著相关。坦索罗辛治疗和TURP分别使17.9%和32.2%的患者夜尿发作次数显著减少。在七个单项症状评分中，这些改善率在夜尿症方面是最低的。
在这项使用选定队列的研究中，BPH患者的夜尿症发生率高于基于社区的研究。尽管我们无法通过观察到的评分变化来估计患者的满意度，但在对BPH进行保守和侵入性治疗后，夜尿症在IPSS的七个症状中的改善率是最低的。
